Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 81-86

  Zugman, André ^a   Gadelha, Ary ^a   Assunção, Idaiane ^a   Sato, João ^b   Ota, Vanessa K ^a   Rocha, Deyvis L ^a   Mari, Jair J ^a   Belangero, Sintia I ^a   Bressan, Rodrigo A ^a   Brietzke, Elisa ^a   Jackowski, Andrea P ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

Cortical thickness; MRI; Refractory; Schizophrenia; Treatment resistant

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BRAIN REGION; CLUSTER ANALYSIS; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE SEVERITY; FEMALE; FOLLOW UP; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; LEFT CAUDAL MIDDLE FRONTAL CORTEX; LEFT SUPERIOR FRONTAL CORTEX; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONTE CARLO METHOD; NON RESISTANT SCHIZOPHRENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SCHIZOPHRENIA; TEMPORAL CORTEX; TREATMENT RESISTANT SCHIZOPHRENIA;

CORTICAL THICKNESS; MRI; REFRACTORY; SCHIZOPHRENIA; TREATMENT RESISTANT;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NERVE NET; PREFRONTAL CORTEX; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84881030629     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.05.002     Document Type: Article

References (53)

1. Barch D.M., Carter C.S., Braver T.S., Sabb F.W., MacDonald A., Noll D.C., Cohen J.D. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 2001, 58(3):280-288.
2. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The risperidone study group. Am. J. Psychiatry 1998, 155(4):499-504.
3. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 2001, 158(4):518-526.
4. Cotter D., Mackay D., Frangou S., Hudson L., Landau S. Cell density and cortical thickness in Heschl's gyrus in schizophrenia, major depression and bipolar disorder. Br. J. Psychiatry 2004, 185:258-259.
5. Ehrlich S., Brauns S., Yendiki A., Ho B., Calhoun V., Schulz S., Gollub R., Sponheim S. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. Schizophr. Bull. 2012, 38(5):1050-1062. (Epub 2011 Mar 1024). 10.1093/schbul/sbr1018.
6. Fischl B. FreeSurfer. NeuroImage 2012, 62(2):774-781.
7. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(20):11050-11055.
8. Friedman H.R., Goldman-Rakic P.S. Coactivation of prefrontal cortex and inferior parietal cortex in working memory tasks revealed by 2DG functional mapping in the rhesus monkey. J. Neurosci. 1994, 14(5 Pt 1):2775-2788.
9. Haijma S., Van H.N., Cahn W., Koolschijn P., Hulshoff P.H., Kahn R. Brain volumes in schizophrenia: a meta-analysis in over 18000 subjects. Schizophr. Bull. 2012, 5:5.
10. Hamilton L.S., Narr K.L., Luders E., Szeszko P.R., Thompson P.M., Bilder R.M., Toga A.W. Asymmetries of cortical thickness: effects of handedness, sex, and schizophrenia. Neuroreport 2007, 18(14):1427-1431.
11. Harvey I., Ron M.A., Du Boulay G., Wicks D., Lewis S.W., Murray R.M. Reduction of cortical volume in schizophrenia on magnetic resonance imaging. Psychol. Med. 1993, 23(3):591-604.
12. Hazlett E.A., Buchsbaum M.S., Haznedar M.M., Newmark R., Goldstein K.E., Zelmanova Y., Glanton C.F., Torosjan Y., New A.S., Lo J.N., Mitropoulou V., Siever L.J. Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr. Res. 2008, 101(1-3):111-123.
13. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., Feldman J.M. Clozapine: a clinical review of adverse effects and management. Ann. Clin. Psychiatry 2003, 15(1):33-48.
14. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the global assessment of functioning (GAF). Br. J. Psychiatry 1995, 166(5):654-659.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
17. Kessler R.C., Birnbaum H., Demler O., Falloon I.R., Gagnon E., Guyer M., Howes M.J., Kendler K.S., Shi L., Walters E., Wu E.Q. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol. Psychiatry 2005, 58(8):668-676.
18. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60(9):878-888.
19. Lieberman J.A. Prediction of outcome in first-episode schizophrenia. J. Clin. Psychiatry 1993, 54:13-17. (Suppl.).
20. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J. Clin. Psychiatry 1999, 60(Suppl. 12):9-12.
21. Lieberman J., Jody D., Geisler S., Vital-Herne J., Alvir J.M., Walsleben J., Woerner M.G. Treatment outcome of first episode schizophrenia. Psychopharmacol. Bull. 1989, 25(1):92-96.
22. Manoach D.S. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr. Res. 2003, 60(2-3):285-298.
23. Mathalon D.H. Challenges associated with application of clinical staging models to psychotic disorders. Biol. Psychiatry 2011, 70(7):600-601.
24. Mattai A., Chavez A., Greenstein D., Clasen L., Bakalar J., Stidd R., Rapoport J., Gogtay N. Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr. Res. 2010, 116(1):44-48.
25. Meltzer H.Y. Treatment-resistant schizophrenia -the role of clozapine. Curr. Med. Res. Opin. 1997, 14(1):1-20.
26. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25(2):233-255.
27. Minzenberg M.J., Laird A.R., Thelen S., Carter C.S., Glahn D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 2009, 66(8):811-822.
28. Mitelman S.A., Buchsbaum M.S. Very poor outcome schizophrenia: clinical and neuroimaging aspects. Int. Rev. Psychiatry 2007, 19(4):345-357.
29. Mitelman S.A., Shihabuddin L., Brickman A.M., Hazlett E.A., Buchsbaum M.S. MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. Am. J. Psychiatry 2003, 160(12):2154-2168.
30. Mitelman S.A., Buchsbaum M.S., Brickman A.M., Shihabuddin L. Cortical intercorrelations of frontal area volumes in schizophrenia. NeuroImage 2005, 27(4):753-770.
31. Mitelman S.A., Brickman A.M., Shihabuddin L., Newmark R.E., Hazlett E.A., Haznedar M.M., Buchsbaum M.S. A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. NeuroImage 2007, 37(2):449-462.
32. Molina V., Reig S., Sarramea F., Sanz J., Francisco Artaloytia J., Luque R., Aragues M., Pascau J., Benito C., Palomo T., Desco M. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 2003, 124(3):153-161.
33. Molina V., Hernandez J.A., Sanz J., Paniagua J.C., Hernandez A.I., Martin C., Matias J., Calama J., Bote B. Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry. Psychiatry Res. 2010, 184(1):16-22.
34. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., Essock S.M., Finnerty M., Marder S.R., Miller D.D., McEvoy J.P., Robinson D.G., Schooler N.R., Shon S.P., Stroup T.S., Miller A.L. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J. Clin. Psychiatry 2007, 68(11):1751-1762.
35. Narayan V.M., Narr K.L., Kumari V., Woods R.P., Thompson P.M., Toga A.W., Sharma T. Regional cortical thinning in subjects with violent antisocial personality disorder or schizophrenia. Am. J. Psychiatry 2007, 164(9):1418-1427.
36. Narr K.L., Toga A.W., Szeszko P., Thompson P.M., Woods R.P., Robinson D., Sevy S., Wang Y., Schrock K., Bilder R.M. Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol. Psychiatry 2005, 58(1):32-40.
37. Nesvag R., Lawyer G., Varnas K., Fjell A.M., Walhovd K.B., Frigessi A., Jonsson E.G., Agartz I. Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophr. Res. 2008, 98(1-3):16-28.
38. Panizzon M.S., Fennema-Notestine C., Eyler L.T., Jernigan T.L., Prom-Wormley E., Neale M., Jacobson K., Lyons M.J., Grant M.D., Franz C.E., Xian H., Tsuang M., Fischl B., Seidman L., Dale A., Kremen W.S. Distinct genetic influences on cortical surface area and cortical thickness. Cereb. Cortex 2009, 19(11):2728-2735.
39. Pantelis C., Lambert T.J. Managing patients with "treatment-resistant" schizophrenia. Med. J. Aust. 2003, 178:S62-S66. (Suppl.).
40. Park S., Puschel J., Sauter B.H., Rentsch M., Hell D. Spatial working memory deficits and clinical symptoms in schizophrenia: a 4-month follow-up study. Biol. Psychiatry 1999, 46(3):392-400.
41. Petrides M., Alivisatos B., Meyer E., Evans A.C. Functional activation of the human frontal cortex during the performance of verbal working memory tasks. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(3):878-882.
42. Schultz C.C., Koch K., Wagner G., Roebel M., Nenadic I., Schachtzabel C., Reichenbach J.R., Sauer H., Schlosser R.G. Complex pattern of cortical thinning in schizophrenia: results from an automated surface based analysis of cortical thickness. Psychiatry Res. 2010, 182(2):134-140.
43. Staal W.G., Hulshoff Pol H.E., Schnack H.G., van Haren N.E., Seifert N., Kahn R.S. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am. J. Psychiatry 2001, 158(7):1140-1142.
44. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008, 102(1-3):1-18.
45. The British Psychological Society and The Royal College of Psychiatrists, 2010. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, Updated ed. ed. British Psychological Society Royal College of Psychiatrists, London.
46. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63(1):106-113.
47. van Veelen N.M., Vink M., Ramsey N.F., van Buuren M., Hoogendam J.M., Kahn R.S. Prefrontal lobe dysfunction predicts treatment response in medication-naive first-episode schizophrenia. Schizophr. Res. 2011, 129(2-3):156-162.
48. Venkatasubramanian G., Jayakumar P.N., Gangadhar B.N., Keshavan M.S. Automated MRI parcellation study of regional volume and thickness of prefrontal cortex (PFC) in antipsychotic-naïve schizophrenia. Acta Psychiatr. Scand. 2008, 117(6):420-431.
49. Wahlbeck K., Cheine M., Essali A., Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry 1999, 156(7):990-999.
50. Wiegand L.C., Warfield S.K., Levitt J.J., Hirayasu Y., Salisbury D.F., Heckers S., Dickey C.C., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E. Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study. Biol. Psychiatry 2004, 55(2):131-140.
51. Wiersma D., Nienhuis F.J., Slooff C.J., Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr. Bull. 1998, 24(1):75-85.
52. Woods B.T., Ward K.E., Johnson E.H. Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment. Schizophr. Res. 2005, 73(2-3):221-228.
53. Yoon U., Lee J.M., Im K., Shin Y.W., Cho B.H., Kim I.Y., Kwon J.S., Kim S.I. Pattern classification using principal components of cortical thickness and its discriminative pattern in schizophrenia. NeuroImage 2007, 34(4):1405-1415.